Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment

被引:11
|
作者
Safer, Abdel-Majed [1 ]
Leporatti, Stefano [2 ]
机构
[1] Kuwait Univ, Fac Sci, Dept Biol Sci, Kuwait, Kuwait
[2] Ist Nanotecnol, CNR Nanotec, I-73100 Lecce, Italy
来源
关键词
chitosan; nanoparticles; drug delivery; antivirals; COVID-19; CHLOROQUINE; VACCINES; INHIBIT; VIRUS;
D O I
10.2147/IJN.S332385
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Chitosan has been investigated in several biological fields, including drug and gene delivery, tissue engineering antiviral and immunological adjuvant methods. It's a cationic copolymer of N-acetyl glucosamine and D-glucosamine with different molecular chain lengths, compositions, and sequences than N-acetyl glucosamine and D-glucosamine. It is biocompatible and cyto-compatible, as well as recyclable and bioresorbable. As effective drug delivery methods, chitosan nanoparticles are shaped into several pathways. The purpose of this article is to provide an overview of its antiviral application as a nanocarrier for antiviral medications, highlighting the benefits, limitations, and downsides. In this review, we will report the most recent COVID-19 vaccination advances. It will also be discussed what the future holds for chitosan nanoparticles in the treatment of coronaviruses.
引用
收藏
页码:8141 / 8158
页数:18
相关论文
共 50 条
  • [41] Antiviral treatment for COVID-19: the evidence supporting remdesivir
    Richardson, Charlotte
    Bhagani, Sanjay
    Pollara, Gabriele
    CLINICAL MEDICINE, 2020, 20 (06)
  • [42] COVID-19 Antiviral and Treatment Candidates: Current Status
    Espano, Erica
    Kim, Dajung
    Kim, Jiyeon
    Park, Song-Kyu
    Kim, Jeong-Ki
    IMMUNE NETWORK, 2021, 21 (01) : 1 - 24
  • [43] Accelerating antiviral drug discovery: lessons from COVID-19
    von Delft, Annette
    Hall, Matthew D.
    Kwong, Ann D.
    Purcell, Lisa A.
    Saikatendu, Kumar Singh
    Schmitz, Uli
    Tallarico, John A.
    Lee, Alpha A. A.
    NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (07) : 585 - 603
  • [44] Investigational antiviral drugs for the treatment of COVID-19 patients
    Samineh Beheshtirouy
    Elnaz Khani
    Sajad Khiali
    Taher Entezari-Maleki
    Archives of Virology, 2022, 167 : 751 - 805
  • [45] Triple antiviral treatment for COVID-19 in an immunocompromised patient
    Dentone, Chiara
    Mikulska, Malgorzata
    Sepulcri, Chiara
    Balletto, Elisa
    De Pace, Vanessa
    Beltramini, Sabrina
    Bassetti, Matteo
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (08) : 2097 - 2099
  • [46] Potential of amentoflavone with antiviral properties in COVID-19 treatment
    Singh, Akhilesh Vikram
    ASIAN BIOMEDICINE, 2021, 15 (04) : 153 - 159
  • [47] A Review on Novel Drug Targets and Future Directions for COVID-19 Treatment
    Wondmkun, Yohannes Tsegyie
    Mohammed, Ousman Ahmed
    BIOLOGICS-TARGETS & THERAPY, 2020, 14 : 77 - 82
  • [48] Antiviral properties of placental growth factors: A novel therapeutic approach for COVID-19 treatment
    Joshi, Meghnad G.
    Kshersagar, Jeevitaa
    Desai, Shashikant R.
    Sharma, Shimpa
    PLACENTA, 2020, 99 : 117 - 130
  • [49] Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment
    Kifle, Zemene Demelash
    Ayele, Akeberegn Gorems
    Enyew, Engidaw Fentahun
    JOURNAL OF ENVIRONMENTAL AND PUBLIC HEALTH, 2021, 2021
  • [50] Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis
    Pitre, Tyler
    Van Alstine, Rebecca
    Chick, Genevieve
    Leung, Gareth
    Mikhail, David
    Cusano, Ellen
    Khalid, Faran
    Zeraatkar, Dena
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (28) : E969 - E980